WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2001085730) PYRIDO' 1,2-ALPHA PYRAZINE AND PIPERIDINE DERIVATIVES AS LIGANDS FOR THE NEUROPEPTIDE Y Y5 RECEPTOR
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2001/085730    International Application No.:    PCT/GB2001/001961
Publication Date: 15.11.2001 International Filing Date: 04.05.2001
Chapter 2 Demand Filed:    20.11.2001    
IPC:
C07D 401/12 (2006.01), C07D 471/04 (2006.01)
Applicants: ASTRAZENECA AB [SE/SE]; S-151 85 Södertälje (SE) (AE, AG, AL, AM, AT, AU, AZ, BA, BB, BE, BF, BG, BJ, BR, BY, BZ, CA, CF, CG, CH, CI, CM, CN, CO, CR, CU, CY, CZ, DE, DK, DM, DZ, EE, ES, FI, FR, GA, GB, GD, GE, GH, GM, GN, GR, GW, HR, HU, ID, IE, IL, IN, IS, IT, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MC, MD, MK, ML, MN, MR, MW, MX, MZ, NE, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, SN, SZ, TD, TG, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW only).
ASTRAZENECA UK LIMITED [GB/GB]; 15 Stanhope Gate, London W1Y 6LN (GB) (MG only).
BLOCK, Michael, Howard [GB/GB]; (GB) (For US Only).
SCHOFIELD, Paul [GB/GB]; (GB) (For US Only)
Inventors: BLOCK, Michael, Howard; (GB).
SCHOFIELD, Paul; (GB)
Agent: BRYANT, Tracey; AstraZeneca, Global Intellectual Property, P.O. Box 272, Mereside, Alderley Park, Macclesfield, Cheshire SK10 4GR (GB)
Priority Data:
0011013.0 09.05.2000 GB
Title (EN) PYRIDO' 1,2-ALPHA PYRAZINE AND PIPERIDINE DERIVATIVES AS LIGANDS FOR THE NEUROPEPTIDE Y Y5 RECEPTOR
(FR) DERIVES DE PYRIDO' 1,2-ALPHA PYRAZINE ET DE PIPERIDINE SERVANT DE LIGANDS AU RECEPTEUR DE NEUROPEPTIDE Y Y5
Abstract: front page image
(EN)Compounds of formula (I) R¿1?—A—R¿2? wherein R¿1? and R¿2? are selected from the following combinations: R¿1? is R¿4? —and R¿2? is —SO¿2? —R¿5?, R¿1? is R¿4? —SO¿2?— and R¿2? is—R¿5?, R¿1? is R¿5?— and R¿2? is—SO¿2?—R¿4?; and R¿1? is R¿5?—SO¿2?—and R¿2? is—R¿4?; A is selected from Group 1a, Group 1b, Group 1c or Group 1d and B, R¿3?, R¿4?, R¿5?, p, q and n are as described within, and their pharmaceutically-acceptable salts, pro-drugs and solvates are described. Also described are processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of disorders mediated by the neuropeptide Y5 receptor.
(FR)La présente invention concerne des composés de formule (I), dans laquelle R¿1? et R¿2? sont choisis parmi les combinaisons suivantes : R¿1? est R¿4? - et R¿2? est - SO¿2? - R¿5?, R¿1? est R¿4? - SO¿2? - et R¿2? est - R¿5?, R¿1? est R¿5? - et R¿2? est - SO¿2? - R¿4?; et R¿1? est R¿5? - SO¿2? - et R¿2? est - R¿4?; A est choisi parmi le groupe 1a, 1b, 1c ou 1d et B, R¿3?, R¿4?, R¿5?, p, q et n sont tels que décrits dans cette invention, ainsi que leurs sels, promédicaments et solvates, acceptables d'un point de vue pharmaceutique. La présente invention concerne également des procédés de préparation de ces composés, des compositions pharmaceutiques les contenant, ainsi que leur utilisation dans le traitement de troubles induits par le récepteur de neuropeptide Y5.
Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
African Regional Intellectual Property Organization (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)